Developer docs
API playgroundTry for free, no card

Search company profiles

Novo Ventures

Full company profile

uuid0007fyn

Namestring
Novo Ventures
Legal namestring
Novo Holdings A/S
Websiteurl
novoholdings.dk
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Novo Holdings A/S is the holding and investment company wholly owned by the Novo Nordisk Foundation, one of the world's largest enterprise foundations. The firm manages Total Assets under Management of DKK 694 billion (EUR 93 billion) as of year-end 2025 and operates through seven specialised investment teams covering the full life cycle: Seed Investments (36 companies, DKK 4 billion portfolio), Venture Investments (53 companies, DKK 17 billion), Principal Investments (15-16 companies, DKK 87-99 billion), Capital Investments (DKK 114 billion diversified book), Planetary Health Investments (25 companies, DKK 8.25 billion), Asia Investments (12 companies, USD 512 million), and Quantum Investments (DKK 1.4 billion committed). It is also the controlling shareholder of Novo Nordisk and Novonesis, holding all A shares and significant B shares in each, with governance obligations written into the Foundation's Articles of Association.

The business is structured as an evergreen investment platform that generates Total Income and Investment Returns through dividends, capital appreciation, and realised gains on the Novo Group companies and on the broader investment portfolio. Novo Holdings invests directly in life science companies (biotechnology, medical technology, bioprocessing) and quantum technologies, while Capital Investments manages a multi-asset book spanning public equities, private equity, real assets, bonds, venture capital and credit. In 2025, the firm recorded Total Income and Investment Returns of DKK 21 billion (EUR 2.7 billion), a 9.2% constant-exchange-rate return on the Investment Portfolio, and a 10-year average return of 8.6%, supported by an active exit cadence (Hemab Therapeutics Nasdaq IPO, Nalu Medical to Boston Scientific, Clario to Thermo Fisher, LimmaTech to Eli Lilly, KabaFusion to Nautic Partners).

Novo Holdings distributes capital through direct proprietary deal flow and through co-investment partnerships with leading healthcare-specialist investors (Bain Capital, OrbiMed, RA Capital, Sofinnova, Forbion, Sanofi Ventures) and pan-European growth platforms such as the Scaleup Europe Fund (EUR 500 million founding commitment). The firm operates from offices in Hellerup (Copenhagen headquarters), Boston, San Francisco, London, Singapore, Shanghai and Mumbai, with around 130 investment professionals and a 54% international workforce. Its competitive positioning rests on patient capital from the Foundation, an in-house SeedLab for early-stage validation, deep life science expertise reinforced by ownership of Novo Nordisk and Novonesis, and an engaged ownership model that combines board representation with cross-portfolio strategic support.

Short descriptiontext

Novo Holdings manages DKK 694 billion in assets for the Novo Nordisk Foundation across life science and capital investment platforms, serving as controlling shareholder of Novo Nordisk and Novonesis globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBagsværd, Denmark
HQ citystring
Bagsværd
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life science venture capital, private equity investments, biotech investment firm, asset management services, growth stage investing
Industry3 codes
PRIMARYFSAAADAH
Family Office Investment Platforms & Direct Investing (PE/VC/Co-Invest)
Financial & Insurance/Asset & Wealth Management/Family Offices (Single- & Multi-Family)
SECONDARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
NAICS code3 codes
  • Offices of Other Holding Companies551112
  • Portfolio Management and Investment Advice523940
  • Management of Companies and Enterprises55111
SIC code1 code
  • Investment Advice6282
Product category
Life Science Investment Management
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Investment Portfolio Returns
TypeManaged Services
Description

Novo Holdings generates returns through managing and investing the assets of the Novo Nordisk Foundation. The company earns returns through capital appreciation, dividends, and realized gains from its investment portfolio spanning life science and capital investments. Returns support the Foundation's philanthropic activities.

novoholdings.dk
2Controlling Shareholder Returns
TypeLicensing Royalties
Description

As controlling shareholder of Novo Nordisk (28.1% equity, 77.3% votes) and Novonesis (25.5% equity, 63.4% votes), Novo Holdings receives dividends and benefits from the success of these world-leading life science companies. Novo Nordisk delivered 10% sales growth in 2025 and Novonesis delivered 7% organic sales growth.

novoholdings.dk
3Life Science Investment Returns
TypeTransaction Fee
Description

Investments in life science companies at all stages (seed through principal/private equity) generate returns through exits, IPOs, and ongoing portfolio value appreciation. In 2025, Total Income and Investment Return was DKK 21 billion.

novoholdings.dk
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
Pricing details1 tier
1Investment Management Services
ModelOtherBilling cadenceMulti-year contract
Notes

Novo Holdings manages assets for the Novo Nordisk Foundation and does not charge external customers for investment management services. The company operates as a wholly-owned subsidiary of the Foundation.

novoholdings.dk
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Novo Holdings A/S is a holding and investment company that manages the assets and wealth of the Novo Nordisk Foundation. It invests in life science companies at all stages of development through dedicated Seed, Venture, Principal, Planetary Health, Asia, and Quantum Investments teams, while also managing a diversified portfolio of equities, bonds, real estate, infrastructure, and private capital investments. Total Assets under Management reached DKK 694 billion (EUR 93 billion) at year-end 2025.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • DKK 21 billion Total Income and Investment Return in 2025
+4 more records
Product overview1 text field

Novo Ventures (Novo Holdings A/S) is a holding and investment company that manages the assets and wealth of the Novo Nordisk Foundation. The company operates a multi-team investment platform comprising Seed Investments, Venture Investments, Principal Investments, Capital Investments, Planetary Health Investments, Asia Investments, and Quantum Investments. These investment teams collectively manage Total Assets under Management of DKK 694 billion as of year-end 2025. The company is the controlling shareholder of Novo Nordisk and Novonesis (the Novo Group companies) and invests in life science companies at all stages of development. In addition to life science investments, the company manages a broad portfolio of equities, bonds, real estate, infrastructure, and private equity assets.

Product and service8 records
1Seed Investments
CategoryInvestment Service
2Venture Investments
CategoryInvestment Service
3Principal Investments
CategoryInvestment Service
4Capital Investments
CategoryInvestment Service
5Planetary Health Investments
CategoryInvestment Service
6Asia Investments
CategoryInvestment Service
7REPAIR Impact Fund
CategoryInvestment Service
8Quantum Investments
CategoryInvestment Service
Scale indicator30 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-06
Description

Novo Holdings partnered with Sampension and European Energy to boost green transition in Denmark and Sweden. Partnership started with DKK 650 million (EUR 87 million) for land purchase for solar and wind farms, with potential investments up to DKK 1.5 billion through debt financing.

2Novo Nordisk Foundation
Strategic tierFlagshipTypeOthers
Description

Novo Nordisk Foundation is the sole owner of Novo Holdings. The Foundation is one of the world's largest enterprise foundations, established in 1924, with a vision to improve people's health and sustainability of society and the planet.

novoholdings.dk
Strategic tierFlagshipTypeOthers
Description

Novo Nordisk is controlled by Novo Holdings with 28.1% equity and 77.3% voting shares. Novo Nordisk is a global healthcare company driving change to defeat serious chronic diseases, built on heritage in diabetes.

Strategic tierFlagshipTypeOthers
Description

Novo Holdings controls Novonesis (formed 2024 by merger of Novozymes and Chr. Hansen) with 25.5% equity and 63.4% votes. Novonesis is a global biosolutions company leveraging microbiology to transform how the world produces, consumes and lives.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Novo Nordisk Foundation initiative to establish one of the world's first fully functional and generally applicable quantum computers, supporting Novo Holdings' Quantum Investments strategy.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Novo Nordisk Foundation initiative fully owned by the Foundation developing quantum materials and quantum chips as well as associated fabrication tools.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

BII is Denmark's official NATO DIANA accelerator site. Deep Tech Lab – Quantum operated by BII is a key partner in the quantum ecosystem alongside Niels Bohr Institute, Technical University of Denmark, Aarhus University, and Danish National Metrology Institute.

Strategic tierCoreTypeOthers
Description

Licensed global rights (excluding Greater China and several Southeast and West Asian countries) for WIN378 anti-TSLP antibody from Kelun Biotech.

9Harbour BioMed
Strategic tierCoreTypeOthers
Description

Licensed global rights (excluding Greater China and several Southeast and West Asian countries) for WIN378 anti-TSLP antibody from Harbour BioMed.

novoholdings.dk
Strategic tierCoreTypeOthers
Description

Licensed global rights (excluding Greater China) for WIN027 bispecific antibody from Qyuns Therapeutics.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

KKR's Health Care Strategic Growth platform invests in growth-stage healthcare companies. Broad incumbent comparable to Novo Holdings Principal Investments given larger overall firm scale and broader sector exposure.

TypeBroad incumbent
Description

Blackstone Life Sciences is the dedicated life sciences arm of Blackstone, investing across stages. Broad incumbent comparable to Novo Holdings given mega-fund scale advantage in PE/VC space globally.

TypeDirect peer
Description

Forbion is a European life sciences venture capital firm investing across stages in biotech and medtech. Comparable to Novo Venture Investments in European focus and stage range; co-investor with Novo on Coultreon Biopharma.

TypeDirect peer
Description

OrbiMed is a dedicated healthcare investment firm managing multiple funds across venture, growth, and public equity stages. Directly comparable to Novo Holdings given its life sciences specialization across stages; co-investor on Windward Bio with Novo Holdings.

TypeDirect peer
Description

Patient Square Capital is a healthcare-dedicated private equity firm investing across growth and buyout stages. Directly comparable to Novo Holdings Principal Investments in stage range and healthcare focus; similar check size profile.

TypeBroad incumbent
Description

Wellington Management is a global investment manager with significant healthcare and life sciences investment capabilities. Broad incumbent comparable to Novo Holdings Capital Investments given institutional asset management scale.

TypeDirect peer
Description

Bain Capital Life Sciences is a healthcare and life sciences-focused investment platform spanning venture through growth equity. Closely comparable to Novo Ventures/Principal Investments in stage range and therapeutic focus; existing co-investor with Novo Holdings in HST Pathways.

TypeDirect peer
Description

RA Capital is a healthcare-focused crossover fund investing across public and private life sciences companies. Directly comparable to Novo Venture Investments given shared crossover investing approach; co-investor with Novo on Windward Bio.

TypeDirect peer
Description

ARCH is a sector-focused venture capital firm creating and investing in life sciences and technology companies from inception. Directly comparable to Novo Seed Investments and early-stage Venture Investments in creating breakthrough biotech companies.

TypeBroad incumbent
Description

Carlyle's Global Healthcare team invests across the healthcare value chain from venture to buyout. Broad incumbent in healthcare PE/VC comparable to Novo Holdings Principal Investments given Carlyle's broader fund portfolio reach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile6 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles32 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment80 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Novo Ventures

Life Science Investment Managementnovoholdings.dk

Novo Holdings manages DKK 694 billion in assets for the Novo Nordisk Foundation across life science and capital investment platforms, serving as controlling shareholder of Novo Nordisk and Novonesis globally.

What Novo Ventures does

Novo Holdings A/S is the holding and investment company wholly owned by the Novo Nordisk Foundation, one of the world's largest enterprise foundations. The firm manages Total Assets under Management of DKK 694 billion (EUR 93 billion) as of year-end 2025 and operates through seven specialised investment teams covering the full life cycle: Seed Investments (36 companies, DKK 4 billion portfolio), Venture Investments (53 companies, DKK 17 billion), Principal Investments (15-16 companies, DKK 87-99 billion), Capital Investments (DKK 114 billion diversified book), Planetary Health Investments (25 companies, DKK 8.25 billion), Asia Investments (12 companies, USD 512 million), and Quantum Investments (DKK 1.4 billion committed). It is also the controlling shareholder of Novo Nordisk and Novonesis, holding all A shares and significant B shares in each, with governance obligations written into the Foundation's Articles of Association.

The business is structured as an evergreen investment platform that generates Total Income and Investment Returns through dividends, capital appreciation, and realised gains on the Novo Group companies and on the broader investment portfolio. Novo Holdings invests directly in life science companies (biotechnology, medical technology, bioprocessing) and quantum technologies, while Capital Investments manages a multi-asset book spanning public equities, private equity, real assets, bonds, venture capital and credit. In 2025, the firm recorded Total Income and Investment Returns of DKK 21 billion (EUR 2.7 billion), a 9.2% constant-exchange-rate return on the Investment Portfolio, and a 10-year average return of 8.6%, supported by an active exit cadence (Hemab Therapeutics Nasdaq IPO, Nalu Medical to Boston Scientific, Clario to Thermo Fisher, LimmaTech to Eli Lilly, KabaFusion to Nautic Partners).

Novo Holdings distributes capital through direct proprietary deal flow and through co-investment partnerships with leading healthcare-specialist investors (Bain Capital, OrbiMed, RA Capital, Sofinnova, Forbion, Sanofi Ventures) and pan-European growth platforms such as the Scaleup Europe Fund (EUR 500 million founding commitment). The firm operates from offices in Hellerup (Copenhagen headquarters), Boston, San Francisco, London, Singapore, Shanghai and Mumbai, with around 130 investment professionals and a 54% international workforce. Its competitive positioning rests on patient capital from the Foundation, an in-house SeedLab for early-stage validation, deep life science expertise reinforced by ownership of Novo Nordisk and Novonesis, and an engaged ownership model that combines board representation with cross-portfolio strategic support.

Novo Ventures firmographics

Firmographics
Name
Novo Ventures
Legal name
Novo Holdings A/S
Website
https://novoholdings.dk
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
11–50 employees
Short description
Novo Holdings manages DKK 694 billion in assets for the Novo Nordisk Foundation across life science and capital investment platforms, serving as controlling shareholder of Novo Nordisk and Novonesis globally.
Ownership category
akta.pro rank

Novo Ventures industry classification

Industry
Product category
Life Science Investment Management
NAICS
Offices of Other Holding Companies (551112), Portfolio Management and Investment Advice (523940), Management of Companies and Enterprises (55111)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSAAADAH
Family Office Investment Platforms & Direct Investing (PE/VC/Co-Invest)
Financial & Insurance/Asset & Wealth Management/Family Offices (Single- & Multi-Family)
SECONDARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)

Keywords

  • Life science venture capital
  • Private equity investments
  • Biotech investment firm
  • Asset management services
  • Growth stage investing

Where Novo Ventures is headquartered

Location

Headquarters

HQ city
Bagsværd
HQ country
Denmark
HQ region
Europe

Offices7 records

Markets served

Novo Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Investment Portfolio Returns: Novo Holdings generates returns through managing and investing the assets of the Novo Nordisk Foundation. The company earns returns through capital appreciation, dividends, and realized gains from its investment portfolio spanning life science and capital investments. Returns support the Foundation's philanthropic activities.
  2. Controlling Shareholder Returns: As controlling shareholder of Novo Nordisk (28.1% equity, 77.3% votes) and Novonesis (25.5% equity, 63.4% votes), Novo Holdings receives dividends and benefits from the success of these world-leading life science companies. Novo Nordisk delivered 10% sales growth in 2025 and Novonesis delivered 7% organic sales growth.
  3. Life Science Investment Returns: Investments in life science companies at all stages (seed through principal/private equity) generate returns through exits, IPOs, and ongoing portfolio value appreciation. In 2025, Total Income and Investment Return was DKK 21 billion.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractInvestment Management Services

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Novo Ventures product offering

Product offering

Core offering

Novo Holdings A/S is a holding and investment company that manages the assets and wealth of the Novo Nordisk Foundation. It invests in life science companies at all stages of development through dedicated Seed, Venture, Principal, Planetary Health, Asia, and Quantum Investments teams, while also managing a diversified portfolio of equities, bonds, real estate, infrastructure, and private capital investments. Total Assets under Management reached DKK 694 billion (EUR 93 billion) at year-end 2025.

Product overview

Novo Ventures (Novo Holdings A/S) is a holding and investment company that manages the assets and wealth of the Novo Nordisk Foundation. The company operates a multi-team investment platform comprising Seed Investments, Venture Investments, Principal Investments, Capital Investments, Planetary Health Investments, Asia Investments, and Quantum Investments. These investment teams collectively manage Total Assets under Management of DKK 694 billion as of year-end 2025. The company is the controlling shareholder of Novo Nordisk and Novonesis (the Novo Group companies) and invests in life science companies at all stages of development. In addition to life science investments, the company manages a broad portfolio of equities, bonds, real estate, infrastructure, and private equity assets.

Differentiator

Problem solved

Functional benefit

Products and services

  • Seed Investments
  • Venture Investments
  • Principal Investments
  • Capital Investments
  • Planetary Health Investments
  • Asia Investments
  • REPAIR Impact Fund
  • Quantum Investments

Quantifiable outcome

  • DKK 21 billion Total Income and Investment Return in 2025
  • +4 more outcomes

Companies that use Novo Ventures

Customer profile

Named customers2 records

Segments7 records

Ideal customer profiles6 records

Novo Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Novo Ventures partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and flagship.

  • European EnergycoreStrategic or Co-development Partner · 6 April 2021Novo Holdings partnered with Sampension and European Energy to boost green transition in Denmark and Sweden. Partnership started with DKK 650 million (EUR 87 million) for land purchase for solar and wind farms, with potential investments up to DKK 1.5 billion through debt financing.
  • Novo Nordisk FoundationflagshipOthersNovo Nordisk Foundation is the sole owner of Novo Holdings. The Foundation is one of the world's largest enterprise foundations, established in 1924, with a vision to improve people's health and sustainability of society and the planet.
  • Novo NordiskflagshipOthersNovo Nordisk is controlled by Novo Holdings with 28.1% equity and 77.3% voting shares. Novo Nordisk is a global healthcare company driving change to defeat serious chronic diseases, built on heritage in diabetes.
  • NovonesisflagshipOthersNovo Holdings controls Novonesis (formed 2024 by merger of Novozymes and Chr. Hansen) with 25.5% equity and 63.4% votes. Novonesis is a global biosolutions company leveraging microbiology to transform how the world produces, consumes and lives.
  • Novo Nordisk Foundation Quantum Computing ProgrammecoreStrategic or Co-development PartnerNovo Nordisk Foundation initiative to establish one of the world's first fully functional and generally applicable quantum computers, supporting Novo Holdings' Quantum Investments strategy.
  • Quantum FoundrycoreStrategic or Co-development PartnerNovo Nordisk Foundation initiative fully owned by the Foundation developing quantum materials and quantum chips as well as associated fabrication tools.
  • BioInnovation Institute (BII)coreStrategic or Co-development PartnerBII is Denmark's official NATO DIANA accelerator site. Deep Tech Lab – Quantum operated by BII is a key partner in the quantum ecosystem alongside Niels Bohr Institute, Technical University of Denmark, Aarhus University, and Danish National Metrology Institute.
  • Kelun BiotechcoreOthersLicensed global rights (excluding Greater China and several Southeast and West Asian countries) for WIN378 anti-TSLP antibody from Kelun Biotech.
  • Harbour BioMedcoreOthersLicensed global rights (excluding Greater China and several Southeast and West Asian countries) for WIN378 anti-TSLP antibody from Harbour BioMed.
  • Qyuns TherapeuticscoreOthersLicensed global rights (excluding Greater China) for WIN027 bispecific antibody from Qyuns Therapeutics.

Scale indicators30 records

Recent moves7 records

Expansion highlights5 records

Novo Ventures competitors and assessment

Company assessment

Broad incumbents

  • KKR Health Care Strategic Growth: KKR's Health Care Strategic Growth platform invests in growth-stage healthcare companies. Broad incumbent comparable to Novo Holdings Principal Investments given larger overall firm scale and broader sector exposure.
  • Blackstone Life Sciences: Blackstone Life Sciences is the dedicated life sciences arm of Blackstone, investing across stages. Broad incumbent comparable to Novo Holdings given mega-fund scale advantage in PE/VC space globally.
  • Wellington Management: Wellington Management is a global investment manager with significant healthcare and life sciences investment capabilities. Broad incumbent comparable to Novo Holdings Capital Investments given institutional asset management scale.
  • Carlyle Global Healthcare: Carlyle's Global Healthcare team invests across the healthcare value chain from venture to buyout. Broad incumbent in healthcare PE/VC comparable to Novo Holdings Principal Investments given Carlyle's broader fund portfolio reach.

Direct peers

  • Forbion: Forbion is a European life sciences venture capital firm investing across stages in biotech and medtech. Comparable to Novo Venture Investments in European focus and stage range; co-investor with Novo on Coultreon Biopharma.
  • OrbiMed: OrbiMed is a dedicated healthcare investment firm managing multiple funds across venture, growth, and public equity stages. Directly comparable to Novo Holdings given its life sciences specialization across stages; co-investor on Windward Bio with Novo Holdings.
  • Patient Square Capital: Patient Square Capital is a healthcare-dedicated private equity firm investing across growth and buyout stages. Directly comparable to Novo Holdings Principal Investments in stage range and healthcare focus; similar check size profile.
  • Bain Capital Life Sciences: Bain Capital Life Sciences is a healthcare and life sciences-focused investment platform spanning venture through growth equity. Closely comparable to Novo Ventures/Principal Investments in stage range and therapeutic focus; existing co-investor with Novo Holdings in HST Pathways.
  • RA Capital Management: RA Capital is a healthcare-focused crossover fund investing across public and private life sciences companies. Directly comparable to Novo Venture Investments given shared crossover investing approach; co-investor with Novo on Windward Bio.
  • ARCH Venture Partners: ARCH is a sector-focused venture capital firm creating and investing in life sciences and technology companies from inception. Directly comparable to Novo Seed Investments and early-stage Venture Investments in creating breakthrough biotech companies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Novo Ventures social profiles

Digital presence

Novo Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Novo Ventures leadership team

Management profile

Number of profiles

Profiles32 records

Novo Ventures subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Novo Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Novo Ventures M&A and investment

M&A and investment

M&A

Investments80 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novo Ventures

What does Novo Ventures do?

Novo Holdings A/S is a holding and investment company that manages the assets and wealth of the Novo Nordisk Foundation. It invests in life science companies at all stages of development through dedicated Seed, Venture, Principal, Planetary Health, Asia, and Quantum Investments teams, while also managing a diversified portfolio of equities, bonds, real estate, infrastructure, and private capital investments. Total Assets under Management reached DKK 694 billion (EUR 93 billion) at year-end 2025.

Is Novo Ventures a public or private company?

Novo Ventures is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Novo Ventures founded?

Novo Ventures was founded in 1999. It employs 11 to 50 people.

Where is Novo Ventures based?

Novo Ventures is headquartered in Bagsværd, Denmark, in the Europe region.

How does Novo Ventures make money?

Three revenue lines are on record. Investment Portfolio Returns are the primary driver. The others are controlling Shareholder Returns and life Science Investment Returns.

Who are Novo Ventures's main competitors?

Broad incumbents on record are KKR Health Care Strategic Growth, Blackstone Life Sciences, Wellington Management and Carlyle Global Healthcare. Direct peers are Forbion, OrbiMed, Patient Square Capital, Bain Capital Life Sciences, RA Capital Management and ARCH Venture Partners.

Does Novo Ventures have an API?

No public API is recorded for Novo Ventures.

What industry is Novo Ventures in?

Novo Ventures's product category is Life Science Investment Management. Its primary akta.pro industry code is FSAAADAH, Family Office Investment Platforms & Direct Investing (PE/VC/Co-Invest), with a secondary code of FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 551112 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Novo HoldingsNovo Holdings publishes its 2025 Venture Investments AnnualNovo Holdings Venture Investments published its 2025 Annual Review, reporting $749 million invested and committed across 25 venture financings in the life sciences sector. The firm facilitated significant exits, including five acquisitions and one IPO for MapLight Therapeutics, while expanding its medtech presence through investments in companies like FIRE1 and Supira Medical.UnquoteForbion hires Novo Ventures' LüneborgForbion appointed Nanna Lüneborg as general partner, bringing her from Novo Ventures. She will manage Forbion's debut growth fund, which closed at EUR 360m, surpassing its EUR 250m target. The fund targets mature clinical-development companies and pre-IPO funding.UnquoteNovo, HBM lead CHF 100m round for NumabNovo Ventures and HBM Partners led a CHF 100m series-C round for Numab Therapeutics, a Swiss multi-specific antibodies developer. The funding will advance its lead drug candidate NM21-1408 into clinical trials and support its oncology and inflammation pipeline. Existing investors also participated.BioCenturyNovo ventures into Asia with Hummingbird’s series C roundNovo Ventures invested $125 million in a series C round for Singapore-based Hummingbird, its first Asia entry. The funding will support two lead programs nearing clinical proof-of-concept and expand its Rational Antibody Discovery platform.PR NewswireNovo Ventures Provides Business Update on an Exceptional YearNovo Ventures, the venture arm of Novo Holdings, published its 2020 review reporting $570 million invested in life sciences across 39 public investments including 9 portfolio company IPOs and 33 venture financings. The firm maintained its position as market leader in Europe with 13 transactions while expanding its team to 28 members and appointing Scott Beardsley as Head of Novo Ventures following Thomas Dyrberg's transition to Senior Advisor. Novo Holdings indicated it will continue investing heavily in life sciences and better healthcare in 2021.PR NewswireNovo Holdings participates in BioGeneration Ventures IV FundNovo Ventures, the ventures arm of Novo Holdings, has participated in the oversubscribed fourth fund of BioGeneration Ventures (BGV), which closed at EUR 140 million. This investment enhances Novo Ventures' access to the Benelux life sciences ecosystem and supports BGV's strategy of building new companies around innovative technology platforms. The fund was also backed by institutional investors and global pharma companies including Bristol Myers Squibb and Eli Lilly.news.cision.comBioStock: Big investment sign of great interest in mitochondrial diseasesReneo Pharmaceuticals announced a 95M USD investment from a consortium led by Novo Ventures and Abingworth. Lund-based Abliva is preparing a phase II/III study with its candidate KL1333 in the second half of 2021.FinSMEs­Reneo Pharmaceuticals Raises $95M in Series B FinancingReneo Pharmaceuticals raised $95M in Series B financing co-led by Novo Ventures and Abingworth. The company also appointed Gregory J. Flesher as CEO, with founding CEO Niall O'Donnell remaining on the board. The funding supports development of REN001, an oral drug for mitochondrial diseases.PR Newswire­Reneo Pharmaceuticals Raises $95 Million in Series B Financing, Co-led by Novo Ventures and AbingworthReneo Pharmaceuticals raised $95 million in a Series B financing round co-led by Novo Ventures and Abingworth, with participation from multiple existing and new investors. The clinical-stage pharmaceutical company also appointed Gregory J. Flesher as President and CEO, and stated the funding will support advancement of REN001 through several key clinical milestones including a global phase 2 study in primary mitochondrial myopathies. Phase 2 and phase 1b clinical trials are planned for early 2021 across sites in the U.S., Australia, and Europe.Nordic 9The Protein Brewery secured a €22 Series A investment led by Novo GrowthThe Protein Brewery, a Dutch protein ingredient producer, raised €22M in a Series A led by Novo Growth. The funds will support R&D, operational costs, and scaling production of its flagship product Fermotein. The company was founded in 2020 from a demerger of BioscienZ.